Servier and generics firms to appeal EU verdict on perindopril 'sweetheart' deals
This article was originally published in SRA
Executive Summary
The European Commission has imposed fines totaling Euros 427.7 million on Servier and five producers of generic medicines for anti-competitive practices – a decision that the French drug maker says sets a "regrettable precedent" for industries that rely on intellectual property1,2.
You may also be interested in...
EU Servier Court Ruling 'Reduces Competition Law Risks For Pharma'
The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.
Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'
Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.
Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'
Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.